Erratum to: Increased Mucosal IL-22 Production of an IL-10RA Mutation Patient Following Anakinra Treatment Suggests Further Mechanism for Mucosal Healing [PDF]
Jian Li +4 more
openalex +1 more source
Inflammatory osteolysis: A conspiracy against bone [PDF]
Abu-Amer +36 more
core +2 more sources
4CPS-160 Efficacy and safety of anakinra and canakinumab for the treatment of IL-36R antagonist deficiency [PDF]
María Sáez-Torres de Vicente +5 more
openalex +1 more source
Rescue Therapy With Continuous Intravenous Anakinra Infusion and Plasma Exchange in Refractory Cytokine Storm of Systemic JIA: A Case Report. [PDF]
Jashmi RA, Sawafi AA, Abrawi SA.
europepmc +1 more source
All available clinical data on anakinra in COVID-19: an updated comprehensive review [PDF]
Marzieh Shahrabi +4 more
openalex +1 more source
Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature [PDF]
Catharina M. Mulders‐Manders +3 more
openalex +1 more source
Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial. [PDF]
Tavoulareas G +13 more
europepmc +1 more source
SAT0626 Anakinra treatment in refractory cases of adult-onset still disease: case series [PDF]
Serdal Uğurlu +4 more
openalex +1 more source
Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review. [PDF]
Inguscio G +9 more
europepmc +1 more source

